UMIN-CTR Clinical Trial

Recruitment status Open public recruiting
Unique ID issued by UMIN UMIN000042212
Receipt No. R000048186
Scientific Title Development of rapid on site cytologic evaluation using artificial intelligence (AI-ROSE) during EUS-FNA
Date of disclosure of the study information 2020/10/22
Last modified on 2020/10/22 (Ver. 1)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Development of rapid on site cytologic evaluation using artificial intelligence (AI-ROSE) during EUS-FNA
Acronym AI-ROSE
Scientific Title Development of rapid on site cytologic evaluation using artificial intelligence (AI-ROSE) during EUS-FNA
Scientific Title:Acronym AI-ROSE
Region
Japan

Condition
Condition Pancreatic Cancer
Classification by specialty
Hepato-biliary-pancreatic medicine
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 To examine the usefulness of diagnosis using artificial intelligence (AI) in ROSE by an endoscopist during EUS-FNA
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Diagnostic ability in ROSE during EUS-FNA for pancreatic tumor using AI
Key secondary outcomes

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
90 years-old >
Gender Male and Female
Key inclusion criteria 1) Patients with a solid pancreatic mass who underwent ROSE during EUS-FNA and have a preparatory structure capable of pathological cytology.
2) Cases with a definitive diagnosis of pancreatitis or pancreatic cancer
Key exclusion criteria Cases without ROSE during EUS-FNA
Target sample size 200

Research contact person
Name of lead principal investigator
1st name REIKO
Middle name
Last name ASHIDA
Organization Wakayama Medical University
Division name Second Department of Internal Medicine
Zip code 641-8509
Address 811-1 Kimiidera, Wakayama City
TEL 073-447-2300
Email rashida@wakayama-med.ac.jp

Public contact
Name of contact person
1st name REIKO
Middle name
Last name ASHIDA
Organization Wakayama Medical University
Division name Second Department of Internal Medicine
Zip code 641-8509
Address 811-1 Kimiidera, Wakayama City
TEL 073-441-0627
Homepage URL
Email ninai@wakayama-med.acj.jp

Sponsor
Institute Wakayama Medical University
Institute
Department

Funding Source
Organization Self funding
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Research Ethics Committee of Wakayama Medical University
Address 811-1 Kimiidera, Wakayama, Wakayama Prefecture
Tel +81-73-447-2300(3692)
Email wa-rinri@wakayama-med.ac.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2020 Year 10 Month 22 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Open public recruiting
Date of protocol fixation
2020 Year 07 Month 17 Day
Date of IRB
2020 Year 09 Month 08 Day
Anticipated trial start date
2020 Year 09 Month 08 Day
Last follow-up date
2023 Year 03 Month 31 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information opt-out

Management information
Registered date
2020 Year 10 Month 22 Day
Last modified on
2020 Year 10 Month 22 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000048186